Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 299

1.

Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer.

Suzuki T, Shinozaki E, Osumi H, Nakayama I, Ota Y, Ichimura T, Ogura M, Wakatsuki T, Ooki A, Takahari D, Suenaga M, Chin K, Yamaguchi K.

Cancer Chemother Pharmacol. 2019 May 7. doi: 10.1007/s00280-019-03855-w. [Epub ahead of print]

PMID:
31065729
2.

Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer.

Osumi H, Shinozaki E, Wakatsuki T, Suenaga M, Ichimura T, Ogura M, Takahari D, Ooki A, Suzuki T, Ota Y, Nakayama I, Chin K, Miki Y, Yamaguchi K.

Int J Cancer. 2019 Apr 9. doi: 10.1002/ijc.32320. [Epub ahead of print]

PMID:
30963570
3.

Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer.

Konishi T, Shinozaki E, Murofushi K, Taguchi S, Fukunaga Y, Nagayama S, Fujimoto Y, Akiyoshi T, Nagasaki T, Suenaga M, Chino A, Kawachi H, Yamamoto N, Ishikawa Y, Oguchi M, Ishizuka N, Ueno M, Yamaguchi K.

Ann Surg Oncol. 2019 Apr 8. doi: 10.1245/s10434-019-07342-7. [Epub ahead of print]

PMID:
30963400
4.

A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study.

Suenaga M, Wakatsuki T, Mashima T, Ogura M, Ichimura T, Shinozaki E, Nakayama I, Osumi H, Ota Y, Takahari D, Chin K, Seimiya H, Yamaguchi K.

Invest New Drugs. 2019 Mar 6. doi: 10.1007/s10637-019-00749-9. [Epub ahead of print]

PMID:
30838483
5.

Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer.

Kobayashi K, Kawakami K, Yokokawa T, Aoyama T, Suzuki K, Wakatsuki T, Suenaga M, Sato H, Sugiyama E, Yamaguchi K, Hama T.

Oncology. 2019;96(4):200-206. doi: 10.1159/000495989. Epub 2019 Feb 14.

PMID:
30763946
6.

Perioperative and prognostic implication of albumin-bilirubin-TNM score in Child-Pugh class A hepatocellular carcinoma.

Sonohara F, Yamada S, Tanaka N, Suenaga M, Takami H, Hayashi M, Niwa Y, Sugimoto H, Hattori N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y.

Ann Gastroenterol Surg. 2018 Sep 27;3(1):65-74. doi: 10.1002/ags3.12212. eCollection 2019 Jan.

7.

1,2- trans Glycosylation via Neighboring Group Participation of 2- O-Alkoxymethyl Groups: Application to One-Pot Oligosaccharide Synthesis.

Karak M, Joh Y, Suenaga M, Oishi T, Torikai K.

Org Lett. 2019 Feb 15;21(4):1221-1225. doi: 10.1021/acs.orglett.9b00220. Epub 2019 Jan 29.

PMID:
30693782
8.

Homeobox C10 Influences on the Malignant Phenotype of Gastric Cancer Cell Lines and its Elevated Expression Positively Correlates with Recurrence and Poor Survival.

Miwa T, Kanda M, Umeda S, Tanaka H, Tanaka C, Kobayashi D, Suenaga M, Hayashi M, Yamada S, Nakayama G, Koike M, Kodera Y.

Ann Surg Oncol. 2019 May;26(5):1535-1543. doi: 10.1245/s10434-019-07166-5. Epub 2019 Jan 23.

PMID:
30673899
9.

Increased Expression of DNAJC12 is Associated with Aggressive Phenotype of Gastric Cancer.

Uno Y, Kanda M, Miwa T, Umeda S, Tanaka H, Tanaka C, Kobayashi D, Suenaga M, Hattori N, Hayashi M, Yamada S, Nakayama G, Fujiwara M, Kodera Y.

Ann Surg Oncol. 2019 Mar;26(3):836-844. doi: 10.1245/s10434-018-07149-y. Epub 2019 Jan 7.

PMID:
30617870
10.

Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial.

Suenaga M, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Heinemann V, Lenz HJ.

Eur J Cancer. 2019 Jan;107:100-114. doi: 10.1016/j.ejca.2018.11.019. Epub 2018 Dec 14.

PMID:
30554073
11.

Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake.

Osumi H, Takahari D, Chin K, Ogura M, Ichimura T, Wakatsuki T, Suzuki T, Ota Y, Nakayama I, Ooki A, Suenaga M, Shinozaki E, Yamaguchi K.

Onco Targets Ther. 2018 Nov 23;11:8301-8307. doi: 10.2147/OTT.S184665. eCollection 2018.

12.

Correction to: Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer.

Yagi S, Wakatsuki T, Yamamoto N, Chin K, Takahari D, Ogura M, Ichimura T, Nakayama I, Osumi H, Shinozaki E, Suenaga M, Fujisaki J, Ishikawa Y, Yamaguchi K, Namikawa K, Horiuchi Y.

Gastric Cancer. 2019 May;22(3):526. doi: 10.1007/s10120-018-0900-4.

13.

Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer.

Nakayama I, Chin K, Takahari D, Ogura M, Ichimura T, Wakatsuki T, Osumi H, Ota Y, Suzuki T, Suenaga M, Shinozaki E, Yamaguchi K.

Cancer Manag Res. 2018 Nov 1;10:5283-5290. doi: 10.2147/CMAR.S179219. eCollection 2018.

14.

Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients.

Suenaga M, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Yamaguchi T, Lenz HJ.

Int J Cancer. 2019 May 15;144(10):2567-2577. doi: 10.1002/ijc.31968. Epub 2018 Dec 14.

PMID:
30411783
15.

Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer.

Yagi S, Wakatsuki T, Yamamoto N, Chin K, Takahari D, Ogura M, Ichimura T, Nakayama I, Osumi H, Shinozaki E, Suenaga M, Fujisaki J, Ishikawa Y, Yamaguchi K, Namikawa K, Horiuchi Y.

Gastric Cancer. 2019 May;22(3):518-525. doi: 10.1007/s10120-018-0887-x. Epub 2018 Oct 17. Erratum in: Gastric Cancer. 2018 Nov 22;:.

16.

Prognostic Impact of Portal System Invasion in Pancreatic Cancer Based on Image Classification.

Morimoto D, Yamada S, Murotani K, Sonohara F, Takami H, Suenaga M, Hayashi M, Niwa Y, Tashiro M, Hattori N, Iwata N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y.

Pancreas. 2018 Nov/Dec;47(10):1350-1356. doi: 10.1097/MPA.0000000000001186.

PMID:
30286011
17.

Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab.

Ushida Y, Shinozaki E, Chin K, Suenaga M, Takahari D, Ozaka M, Ogura M, Ichimura T, Wakatsuki T, Yamaguchi K.

Case Rep Oncol. 2018 Aug 29;11(2):601-608. doi: 10.1159/000492568. eCollection 2018 May-Aug.

18.

Copine 5 expression predicts prognosis following curative resection of esophageal squamous cell carcinoma.

Umeda S, Kanda M, Koike M, Tanaka H, Miwa T, Tanaka C, Kobayashi D, Suenaga M, Hayashi M, Yamada S, Nakayama G, Kodera Y.

Oncol Rep. 2018 Dec;40(6):3772-3780. doi: 10.3892/or.2018.6742. Epub 2018 Sep 27.

PMID:
30272363
19.

Expression of sushi domain containing two reflects the malignant potential of gastric cancer.

Umeda S, Kanda M, Miwa T, Tanaka H, Tanaka C, Kobayashi D, Suenaga M, Hattori N, Hayashi M, Yamada S, Nakayama G, Fujiwara M, Kodera Y.

Cancer Med. 2018 Oct;7(10):5194-5204. doi: 10.1002/cam4.1793. Epub 2018 Sep 27.

20.

Clinical Impact of Neoadjuvant Therapy on Nutritional Status in Pancreatic Cancer.

Tashiro M, Yamada S, Sonohara F, Takami H, Suenaga M, Hayashi M, Niwa Y, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y.

Ann Surg Oncol. 2018 Oct;25(11):3365-3371. doi: 10.1245/s10434-018-6699-8. Epub 2018 Aug 10.

PMID:
30097739
21.

Comparison of the Survival Outcomes of Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms.

Yamada S, Fujii T, Hirakawa A, Takami H, Suenaga M, Hayashi M, Niwa Y, Hattori N, Iwata N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y.

Pancreas. 2018 Sep;47(8):974-979. doi: 10.1097/MPA.0000000000001110.

PMID:
30028445
22.

Impact of the Controlling Nutritional Status Score on the Prognosis After Curative Resection of Pancreatic Ductal Adenocarcinoma.

Kato Y, Yamada S, Suenaga M, Takami H, Niwa Y, Hayashi M, Iwata N, Kanda M, Tanaka C, Nakayama G, Koike M, Fujiwara M, Kodera Y.

Pancreas. 2018 Aug;47(7):823-829. doi: 10.1097/MPA.0000000000001105.

PMID:
29975352
23.

Validation Strategy for Ultrasensitive Mutation Detection.

Debeljak M, Noë M, Riel SL, Haley LM, Norris AL, Anderson DA, Adams EM, Suenaga M, Beierl KF, Lin MT, Goggins MG, Gocke CD, Eshleman JR.

Mol Diagn Ther. 2018 Oct;22(5):603-611. doi: 10.1007/s40291-018-0350-z.

PMID:
29974360
24.

Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer.

Tanaka N, Yamada S, Sonohara F, Suenaga M, Hayashi M, Takami H, Niwa Y, Hattori N, Iwata N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y.

Sci Rep. 2018 Jun 29;8(1):9846. doi: 10.1038/s41598-018-28253-9.

25.

Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer.

Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Cremolini C, Lonardi S, Bergamo F, Ning Y, Yamamoto N, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Yamaguchi T, Stintzing S, Heinemann V, Loupakis F, Falcone A, Lenz HJ.

Pharmacogenomics J. 2018 Sep;18(5):623-632. doi: 10.1038/s41397-018-0030-8. Epub 2018 Jun 21.

26.

Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands.

Nonomiya Y, Yokokawa T, Kawakami K, Kobayashi K, Aoyama T, Takiguchi T, Sugisaki T, Suzuki K, Suenaga M, Wakatsuki T, Yamaguchi K, Sugimoto Y, Hama T.

Oncol Res. 2019 May 7;27(5):551-556. doi: 10.3727/096504018X15291727589740. Epub 2018 Jun 18.

PMID:
29914591
27.

Kaemgalangol A: Unusual seco-isopimarane diterpenoid from aromatic ginger Kaempferia galanga.

Swapana N, Tominaga T, Elshamy AI, Ibrahim MAA, Hegazy MF, Brajakishor Singh C, Suenaga M, Imagawa H, Noji M, Umeyama A.

Fitoterapia. 2018 Sep;129:47-53. doi: 10.1016/j.fitote.2018.06.010. Epub 2018 Jun 18.

PMID:
29913194
28.

Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer.

Osumi H, Shinozaki E, Mashima T, Wakatsuki T, Suenaga M, Ichimura T, Ogura M, Ota Y, Nakayama I, Takahari D, Chin K, Miki Y, Yamaguchi K.

Cancer Sci. 2018 Aug;109(8):2567-2575. doi: 10.1111/cas.13698. Epub 2018 Jul 13.

29.

SYT7 acts as a driver of hepatic metastasis formation of gastric cancer cells.

Kanda M, Tanaka H, Shimizu D, Miwa T, Umeda S, Tanaka C, Kobayashi D, Hattori N, Suenaga M, Hayashi M, Iwata N, Yamada S, Fujiwara M, Kodera Y.

Oncogene. 2018 Sep;37(39):5355-5366. doi: 10.1038/s41388-018-0335-8. Epub 2018 Jun 1.

PMID:
29858600
30.

Pattern-Specific Transcriptomics Identifies ASGR2 as a Predictor of Hematogenous Recurrence of Gastric Cancer.

Tanaka H, Kanda M, Miwa T, Tanaka C, Kobayashi D, Umeda S, Shibata M, Suenaga M, Hattori N, Hayashi M, Iwata N, Yamada S, Nakayama G, Fujiwara M, Kodera Y.

Mol Cancer Res. 2018 Sep;16(9):1420-1429. doi: 10.1158/1541-7786.MCR-17-0467. Epub 2018 May 21.

PMID:
29784667
31.

A novel dual-marker expression panel for easy and accurate risk stratification of patients with gastric cancer.

Kanda M, Murotani K, Tanaka H, Miwa T, Umeda S, Tanaka C, Kobayashi D, Hayashi M, Hattori N, Suenaga M, Yamada S, Nakayama G, Fujiwara M, Kodera Y.

Cancer Med. 2018 Jun;7(6):2463-2471. doi: 10.1002/cam4.1522. Epub 2018 May 7.

32.

Integrated multigene expression panel to prognosticate patients with gastric cancer.

Kanda M, Murotani K, Tanaka H, Miwa T, Umeda S, Tanaka C, Kobayashi D, Hayashi M, Hattori N, Suenaga M, Yamada S, Nakayama G, Fujiwara M, Kodera Y.

Oncotarget. 2018 Apr 10;9(27):18775-18785. doi: 10.18632/oncotarget.24661. eCollection 2018 Apr 10.

33.

Genome-Wide Somatic Copy Number Alterations and Mutations in High-Grade Pancreatic Intraepithelial Neoplasia.

Hata T, Suenaga M, Marchionni L, Macgregor-Das A, Yu J, Shindo K, Tamura K, Hruban RH, Goggins M.

Am J Pathol. 2018 Jul;188(7):1723-1733. doi: 10.1016/j.ajpath.2018.03.012. Epub 2018 Apr 22.

PMID:
29684357
34.

Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer.

Tamura K, Yu J, Hata T, Suenaga M, Shindo K, Abe T, MacGregor-Das A, Borges M, Wolfgang CL, Weiss MJ, He J, Canto MI, Petersen GM, Gallinger S, Syngal S, Brand RE, Rustgi A, Olson SH, Stoffel E, Cote ML, Zogopoulos G, Potash JB, Goes FS, McCombie RW, Zandi PP, Pirooznia M, Kramer M, Parla J, Eshleman JR, Roberts NJ, Hruban RH, Klein AP, Goggins M.

Proc Natl Acad Sci U S A. 2018 May 1;115(18):4767-4772. doi: 10.1073/pnas.1720588115. Epub 2018 Apr 18.

35.

Troponin I2 as a Specific Biomarker for Prediction of Peritoneal Metastasis in Gastric Cancer.

Sawaki K, Kanda M, Miwa T, Umeda S, Tanaka H, Tanaka C, Kobayashi D, Suenaga M, Hattori N, Hayashi M, Yamada S, Nakayama G, Fujiwara M, Kodera Y.

Ann Surg Oncol. 2018 Jul;25(7):2083-2090. doi: 10.1245/s10434-018-6480-z. Epub 2018 Apr 16.

PMID:
29663169
36.

Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker.

Shinozaki E, Tanabe K, Akiyoshi T, Tsuchida T, Miyazaki Y, Kojima N, Igarashi M, Ueno M, Suenaga M, Mizunuma N, Yamaguchi K, Nakayama K, Iijima S, Yamaguchi T.

BMC Cancer. 2018 Apr 11;18(1):406. doi: 10.1186/s12885-018-4252-6.

37.

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer.

Wakatsuki T, Yamamoto N, Sano T, Chin K, Kawachi H, Takahari D, Ogura M, Ichimura T, Nakayama I, Osumi H, Matsushima T, Suenaga M, Shinozaki E, Hiki N, Ishikawa Y, Yamaguchi K.

J Gastroenterol. 2018 Nov;53(11):1186-1195. doi: 10.1007/s00535-018-1464-0. Epub 2018 Apr 9.

38.

Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel.

Fukuda N, Takahari D, Wakatsuki T, Osumi H, Nakayama I, Matsushima T, Ichimura T, Ogura M, Ozaka M, Suenaga M, Shinozaki E, Chin K, Yamaguchi K.

Oncotarget. 2018 Mar 8;9(20):15219-15227. doi: 10.18632/oncotarget.24635. eCollection 2018 Mar 16.

39.

Significance of Lysyl oxidase‑like 2 gene expression on the epithelial‑mesenchymal status of hepatocellular carcinoma.

Ninomiya G, Yamada S, Hayashi M, Takeda S, Suenaga M, Takami H, Kanda M, Iwata N, Niwa Y, Tanaka C, Kobayashi D, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y.

Oncol Rep. 2018 Jun;39(6):2664-2672. doi: 10.3892/or.2018.6349. Epub 2018 Apr 2.

PMID:
29620290
40.

Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.

Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Ning Y, Cremolini C, Antoniotti C, Borelli B, Mashima T, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Lonardi S, Yamaguchi T, Falcone A, Loupakis F, Lenz HJ.

Clin Colorectal Cancer. 2018 Jun;17(2):e395-e414. doi: 10.1016/j.clcc.2018.02.010. Epub 2018 Feb 27.

PMID:
29606345
41.

Significance of Preoperative Systemic Inflammation Score in Short-Term and Long-Term Outcomes of Patients with Pathological T2-4 Gastric Cancer After Radical Gastrectomy.

Sato B, Kanda M, Tanaka C, Kobayashi D, Iwata N, Hattori N, Suenaga M, Hayashi M, Yamada S, Murotani K, Fujiwara M, Kodera Y.

World J Surg. 2018 Oct;42(10):3277-3285. doi: 10.1007/s00268-018-4597-7.

PMID:
29560531
42.

Serum vitamin D in patients with mild cognitive impairment and Alzheimer's disease.

Ouma S, Suenaga M, Bölükbaşı Hatip FF, Hatip-Al-Khatib I, Tsuboi Y, Matsunaga Y.

Brain Behav. 2018 Feb 9;8(3):e00936. doi: 10.1002/brb3.936. eCollection 2018 Mar.

43.

NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients.

Schirripa M, Zhang W, Yang D, Cao S, Okazaki S, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Alberti G, West JD, Lonardi S, Khoukaz T, Bergamo F, Battaglin F, Antoniotti C, Falcone A, Stintzing S, Heinemann V, Lenz HJ.

PLoS One. 2018 Mar 9;13(3):e0193640. doi: 10.1371/journal.pone.0193640. eCollection 2018.

44.

A Feasibility Study of Capecitabine and Oxaliplatin for Patients with Stage II/III Colon Cancer -ACTOR Study.

Suenaga M, Akiyoshi T, Shinozaki E, Fujimoto Y, Matsusaka S, Konishi T, Nagayama S, Fukunaga Y, Kawakami K, Yokokawa T, Sugisaki T, Ueno M, Yamaguchi T.

Anticancer Res. 2018 Mar;38(3):1741-1747.

PMID:
29491111
45.

Pancreatic Juice Mutation Concentrations Can Help Predict the Grade of Dysplasia in Patients Undergoing Pancreatic Surveillance.

Suenaga M, Yu J, Shindo K, Tamura K, Almario JA, Zaykoski C, Witmer PD, Fesharakizadeh S, Borges M, Lennon AM, Shin EJ, Canto MI, Goggins M.

Clin Cancer Res. 2018 Jun 15;24(12):2963-2974. doi: 10.1158/1078-0432.CCR-17-2463. Epub 2018 Jan 4.

46.

A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab.

Berger MD, Stintzing S, Heinemann V, Cao S, Yang D, Sunakawa Y, Matsusaka S, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini A, Zhang W, Cremolini C, Falcone A, Loupakis F, Lenz HJ.

Clin Cancer Res. 2018 Feb 15;24(4):784-793. doi: 10.1158/1078-0432.CCR-17-1663. Epub 2017 Dec 5.

47.

The Effect of Pancreatic Juice Collection Time on the Detection of KRAS Mutations.

Suenaga M, Dudley B, Karloski E, Borges M, Irene Canto M, Brand RE, Goggins M.

Pancreas. 2018 Jan;47(1):35-39. doi: 10.1097/MPA.0000000000000956.

48.

Comprehensive analysis of gene expression profiles reveals novel candidates of chemotherapy resistant factors in canine lymphoma.

Suenaga M, Tomiyasu H, Watanabe M, Ogawa K, Motegi T, Goto-Koshino Y, Ohno K, Sugano S, Skorupski KA, Tsujimoto H.

Vet J. 2017 Oct;228:18-21. doi: 10.1016/j.tvjl.2017.10.002. Epub 2017 Oct 8.

PMID:
29153103
49.

An integrated multigene expression panel to predict long-term survival after curative hepatectomy in patients with hepatocellular carcinoma.

Kanda M, Murotani K, Sugimoto H, Miwa T, Umeda S, Suenaga M, Hayashi M, Hattori N, Tanaka C, Kobayashi D, Yamada S, Fujiwara M, Kodera Y.

Oncotarget. 2017 Aug 19;8(41):71070-71079. doi: 10.18632/oncotarget.20369. eCollection 2017 Sep 19.

50.

Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.

Berger MD, Stintzing S, Heinemann V, Yang D, Cao S, Sunakawa Y, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Soni S, Zhang W, Falcone A, Loupakis F, Lenz HJ.

Ann Oncol. 2017 Nov 1;28(11):2780-2785. doi: 10.1093/annonc/mdx412.

Supplemental Content

Loading ...
Support Center